Under the third-tier compliance regulations, which statement best describes 21 CFR Part 7?

Under the third-tier compliance regulations, which statement best describes 21 CFR Part 7?

• A. Enforcement policy for drugs and medical devices
• B. Clinical trial guidelines
• C. Labeling standards for medical devices
• D. Pharmacovigilance requirements

Answer: (A)

21 CFR Part 7 defines the FDA’s enforcement policy for drugs and medical devices. It explains how the agency responds to noncompliance, including what enforcement actions may be pursued (such as warnings, penalties, seizures, or injunctions) and the factors that influence the chosen remedy. This is what makes it the best description for Part 7: it is specifically about how the FDA enforces compliance rather than prescribing how trials are conducted, how products must be labeled, or how safety monitoring is performed. Clinical trial guidance is governed by other regulatory provisions that cover study design, ethics, and approvals. Labeling standards for medical devices are set in different parts that address labeling content and format. Pharmacovigilance requirements pertain to postmarketing safety reporting and monitoring, located in other sections focused on surveillance and adverse event reporting.

21 CFR Part 7 defines the FDA’s enforcement policy for drugs and medical devices. It explains how the agency responds to noncompliance, including what enforcement actions may be pursued (such as warnings, penalties, seizures, or injunctions) and the factors that influence the chosen remedy. This is what makes it the best description for Part 7: it is specifically about how the FDA enforces compliance rather than prescribing how trials are conducted, how products must be labeled, or how safety monitoring is performed.

Clinical trial guidance is governed by other regulatory provisions that cover study design, ethics, and approvals. Labeling standards for medical devices are set in different parts that address labeling content and format. Pharmacovigilance requirements pertain to postmarketing safety reporting and monitoring, located in other sections focused on surveillance and adverse event reporting.